Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This research study is investigating a new medication called IDE196 for people with certain advanced solid cancers, including a type of eye cancer called uveal melanoma, skin cancer, or bowel cancer. These cancers must have particular genetic faults, known as GNAQ/11 mutations or PRKC fusions. The main goals are to find out if IDE196 is safe and how well it works. Researchers are testing IDE196 on its own and in combination with two other approved cancer drugs, binimetinib and crizotinib. The study has different stages: an early stage (Phase 1) to find the right dose, and a later stage (Phase 2) to see how effective that dose is. Some parts of the study looking at IDE196 alone or with binimetinib have already finished taking new patients.
Auf einen Blick
Worum geht es in dieser Studie?
This research study is designed to help us learn more about a new medicine called IDE196. It's for people who have advanced solid cancers, which means the cancer has spread from where it started. Specifically, it's for cancers that have certain genetic changes or 'faults' – imagine a tiny spelling mistake in the cancer's instruction manual – called GNAQ or GNA11 mutations, or PRKC fusions. These faults can be found in different types of cancer, including melanoma (a type of skin cancer, and specifically a rare kind that affects the eye called uveal melanoma) and bowel cancer, as well as other solid tumours.
The main idea behind this study is to see if IDE196 can safely and effectively treat these cancers. Researchers are testing IDE196 in a few ways: they're giving it on its own, and they're also trying it in combination with two other existing cancer drugs, binimetinib and crizotinib. The study is split into stages. Earlier stages focused on finding the safest and most effective dose of IDE196, both by itself and in combination with the other drugs. Later stages focused on seeing how well these doses work against the cancer.
It's important to know that some parts of this study have already finished taking new patients. For example, the parts looking at IDE196 on its own and IDE196 combined with binimetinib are no longer enrolling. This kind of research helps doctors understand new treatments better, so they can find new ways to help people living with cancer.
Wichtige Erkenntnisse
- This study investigates a new drug, IDE196, for advanced cancers with specific genetic changes.
- It's exploring IDE196 alone and in combination with other existing cancer drugs.
- The study aims to check the safety and effectiveness of IDE196.
- It targets cancers like uveal melanoma, cutaneous melanoma, and colorectal cancer.
- Some parts of the study are no longer accepting new patients.
Wer könnte berechtigt sein?
To join this study, you need to be at least 18 years old. You must have a diagnosis of certain advanced solid cancers, such as metastatic uveal melanoma (a type of eye cancer that has spread), cutaneous melanoma (skin cancer), or bowel cancer, and these cancers need to have specific genetic changes (GNAQ/11 mutations or PRKC fusions). Your cancer might be new or it might have come back after previous treatments.
There are also some general health checks. For example, your organs (like your liver and kidneys) need to be working well, and you should be generally well enough to take part. For women who could become pregnant and men, you would need to use effective birth control during the study.
Some things might mean you can't join. For instance, if you've already had a specific type of treatment called a PKC inhibitor, or if you have certain infections like HIV or active Hepatitis B or C. Also, if your cancer has spread to your brain and is causing symptoms, you usually wouldn't be able to join. Your doctor will carefully review all your medical information to see if this study is right for you.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie mindestens 18 Jahre alt?
- Do you have advanced uveal melanoma, cutaneous melanoma, colorectal cancer, or another solid tumour?
- Does your cancer have GNAQ/11 mutations or PRKC fusions?
- Are you generally well enough to take part and do your organs work properly?
- Have you discussed birth control if you are of childbearing potential?
Was beinhaltet die Teilnahme?
If you join this study, you would receive the new drug IDE196, either on its own or in combination with binimetinib or crizotinib. The study involves regular visits to the hospital for checks, which would include blood tests, scans (like CT scans) to see how the cancer is responding, and general health assessments. You'd also be asked questions about how you're feeling and any side effects you might be experiencing. Some people might need to have a new biopsy (a small sample of tissue taken) if the doctors need more information about their cancer. The exact number of visits and the total length of time you'd be in the study would depend on which part of the study you join and how your body responds to the treatment. This will all be explained in detail by the study team.
Potenzielle Risiken und Vorteile
Standorte (15)
- UCLA Medizinisches ZentrumVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Rekrutierung
- San Francisco Oncology AssociatesVerifizierte PostleitzahlSan Francisco, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- SCRI - DenverVerifizierte PostleitzahlDenver, Vereinigte Staaten· Rekrutierung
- Universität von IowaVerifizierte PostleitzahlIowa City, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Cancer Hematology Centers Western MichiganVerifizierte PostleitzahlGrand Rapids, United States· Aktiv, aber nicht rekrutierend
- Columbia University Medical Center - Herbert Irving PavilionVerifizierte PostleitzahlNew York, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Duke UniversitätsklinikumVerifizierte PostleitzahlDurham, Vereinigte Staaten· Rekrutierung
- University of Cincinnati Cancer CenterVerifizierte PostleitzahlCincinnati, Vereinigte Staaten· Rekrutierung
- The Cleveland Clinic FoundationVerifizierte PostleitzahlCleveland, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Sidney Kimmel Cancer Center at Thomas Jefferson UniversityVerifizierte PostleitzahlPhiladelphia, Vereinigte Staaten· Rekrutierung
- The Sarah Cannon Research Institute/Tennessee OncologyVerifizierte PostleitzahlNashville, Vereinigte Staaten· Rekrutierung
- The University of Texas MD Anderson Cancer CenterVerifizierte PostleitzahlHouston, Vereinigte Staaten· Rekrutierung
Häufige Fragen
What is IDE196?
IDE196 is a new experimental drug being tested to treat certain advanced cancers with specific genetic changes.
What kind of cancers is this study for?
This study is for advanced solid cancers like a type of eye cancer (uveal melanoma), skin cancer (cutaneous melanoma), or bowel cancer, that have specific genetic changes called GNAQ/11 mutations or PRKC fusions.
Is IDE196 given alone or with other drugs?
IDE196 is being tested both on its own and in combination with two approved cancer drugs, binimetinib and crizotinib.
Are new patients still being accepted into this study?
Some parts of the study, specifically looking at IDE196 alone and IDE196 with binimetinib, have finished taking new patients. Your doctor can tell you if any other parts are still open.
What are GNAQ/11 mutations or PRKC fusions?
These are specific genetic changes or 'faults' found in the cancer cells that the new drug, IDE196, is designed to target.
Wie Sie mehr erfahren können
IDEAYA Clinical Trials
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.